Health Condition 1: L100- Pemphigus vulgaris Health Condition 2: L100- Pemphigus vulgaris
Conditions
Interventions
Intervention1: RITUXIMAB: Group A will receive conventional dose Rituximab (1000 mg, 2 doses, 2 weeks apart) according to rheumatoid arthritis protocol.
Control Intervention1: RITUXIMAB: Group B will
Sponsors
DEPARTMENT OF DERMATOLOGY
Eligibility
Inclusion criteria
Inclusion criteria: PATIENTS OF PEMPHIGUS VULGARIS OR PEMPHIGUS FOLIACEOUS IN THE ABOVE MENTIONED AGE GROUP WITH SIGNIFICANT CLINICAL DISEASE WITH PDAI( PEMPHIGUS DISEASE ACTIVITY INDEX) SCORE >15 AND WHO ARE WILLING FOR MONTHLY FOLLOW UP VISITS FOR 12 MONTHS.
Exclusion criteria
Exclusion criteria: PATIENTS WITH ACTIVE OR LATENT INFECTIONS LIKE HEPATITIS, TB OR SEPSIS.PREGNANT AND LACTATING FEMALES, PATIENTS WITH KNOWN CARDIAC ABNORMALITIES OR ARRHYTHMIA, SEVERELY DECREASED BONE MARROW FUNCTIONS, KNOWN HYPERSENSITIVITY TO MURINE PROTEINS OR ORAL CORTICOSTEROIDS. PATIENTS WHO HAVE RECEIVED RITUXIMAB IN PRECEDING 12 MONTHS OR DEXAMETHASONE PULSE THERAPY IN PRECEDING 3 MONTHS WILL ALSO BE EXCLUDED.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| COMPLETE REMISSION ON MINIMAL THERAPY AND COMPLETE REMISSION OFF THERAPY.Timepoint: COMPLETE REMISSION ON MINIMAL THERAPY AND COMPLETE REMISSION OFF THERAPY. | — |
Secondary
| Measure | Time frame |
|---|---|
| IMMUNOLOGICAL RE POPULATION OF B LYMPHOCYTES OR CLINICAL RELAPSE OF THE DISEASETimepoint: MONTHLY VISITS FOR 12 MONTHS | — |
Countries
India
Contacts
Public ContactNAMRATA
PGIMER
Outcome results
None listed